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Abstract
Background: The regeneration of peripheral nerve is associated with a change in the alternative
splicing of the fibronectin primary gene transcript to re-express embryonic isoforms containing a
binding site for α4β1 integrins that promote neurite outgrowth. Here we use PC12 cells to
examine the role of the interaction between paxillin and the α4 integrin cytoplasmic domain in
neurite outgrowth.
Results:  Expression of α4 with mutations in the paxillin-binding domain reduced neurite
outgrowth on recombinant embryonic fibronectin fragments relative to wild type α4. Over-
expression of paxillin promoted neurite outgrowth while a mutant isoform lacking the LD4 domain
implicated in the regulation of ARF and Rac GTPases was less effective. Optimal α4-mediated
migration in leucocytes requires spatial regulation of α4 phosphorylation at Ser988, a post-
translational modification that blocks paxillin binding to the integrin cytoplasmic domain. In keeping
with this α4(S988D), which mimics phosphorylated α4, did not promote neurite outgrowth.
However, α4 was not phosphorylated in the PC12 cells, and a non-phosphorylatable α4(S988A)
mutant promoted neurite outgrowth indistinguishably from the wild type integrin.
Conclusion: We establish the importance of the α4 integrin-paxillin interaction in a model of
axonal regeneration and highlight differing dependence on phosphorylation of α4 for extension of
neuronal growth cones and migration of non-neural cells.
Background
Regrowth of the peripheral nervous system (PNS) after
injuries such as axotomy is associated with changes in the
expression of extracellular matrix (ECM) molecules in the
environment traversed by the regenerating growth cones
[1]. These changes may promote regeneration in at least
two different ways. First, by generating increased levels of
molecules such as laminin (Ln) and fibronectin (Fn) that
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can promote neurite outgrowth in cell culture and are
therefore likely to promote regeneration in vivo [2,3]. Sec-
ond, by altering the pattern of alternative splicing so as to
switch from isoforms of ECM proteins expressed in adult
nerve to those expressed earlier during a time of axon
growth in development. An example of the second mech-
anism is provided by Fn, whose primary gene transcript is
alternatively spliced in three regions [4-9]. Two of these
include or exclude single Fn type III repeats (EIIIA and
EIIIB) while the third partially or completely excludes a
region (V or IIICS) that contains a cell binding sequence
Leu-Asp-Val (LDV) recognised by the integrin α4β1
[10,11]. While these regions are excluded from adult Fns
in a cell and tissue specific pattern [12-14], we have previ-
ously found that sciatic nerve injury and regeneration in
the adult rat is associated with a change in the pattern of
alternative splicing and the re-expression of embryonic
Fns that include all these regions [15,16].
Recombinant Fns that include the entire V region promote
neurite outgrowth from dorsal root ganglion (DRG) neu-
rons or PC12 cells (a cell line model of PNS neurones)
more effectively than those containing only the RGD
sequence present in the 10th type III repeat present in all
Fns [17]. As the α4 integrin subunit is expressed on regen-
erating growth cones in vivo, we have therefore proposed
that the re-expression of embryonic Fns following injury
contributes to regeneration of the adult PNS by enhancing
α4β1 integrin signalling [17]. The identification of α4
integrins as part of the regenerative mechanism in the PNS
is of particular interest as these integrins play an impor-
tant role in cell migration in other cell types [18,19]. The
adaptor protein, paxillin, which binds directly to the α4
cytoplasmic domain, is an important downstream signal-
ling molecule in this process [20]. Transgenic knock-in
mice expressing only α4 integrin with a Y991A mutation
within the paxillin binding site that blocks the interaction
show impaired leucocyte recruitment during inflamma-
tion [21]. A physiological modification that blocks bind-
ing of paxillin is generated by phosphorylation of the α4
integrin cytoplasmic domain, detected in certain T cell
lines using an antiserum raised against a synthetic peptide
containing phosphoserine at Ser988 [22]. Phosphorylation
is localised to the leading edge of migrating CHO cells
[23], and the reversibility of paxillin binding enabled by
phosphorylation and dephosphorylation of α4 may be
important for migration, as both S988A (that inhibits
phosphorylation) and S988D (that mimics phosphoryla-
tion) mutations inhibit migration in cell culture [24]. We
have shown previously that paxillin is also associated spe-
cifically with α4 in DRG neurons and PC12 cells [17]. This
suggests the hypothesis that paxillin also makes an essen-
tial contribution to α4-mediated growth cone motility
and PNS regeneration by virtue of the association with the
integrin cytoplasmic domain. Here we test this hypothesis
by examining the requirement for the α4-paxillin interac-
tion in neurite outgrowth and find that the interaction is
required; however, in contrast to non-neuronal cell migra-
tion, α4 phosphorylation is dispensable for neurite out-
growth.
Results
To examine α4-mediated neurite outgrowth we used
PC12 cells as model neurons. These cells do not express
α4 integrin and transfection with α4 enables them to
manifest neurite outgrowth on Fn isoforms that contain
the α4 integrin binding site [17]. To assess the require-
ment for paxillin binding to the α4 cytoplasmic domain
for this neurite outgrowth, we first expressed α4 subunits
into which alanine substitutions had been inserted into
either or both of two amino acids essential for paxillin
binding; Glu983 and Tyr991 [25]. As controls we expressed
either full-length α4 or α4 lacking the cytoplasmic
domain sequences C-terminal to the GFFKR motif (Fig
1A). To demonstrate the expected effects of these muta-
tions on paxillin binding, we immunoprecipitated lysates
of the PC12 cells with antibodies against the extracellular
domain of α4 and then western blotted the protein com-
plexes pulled down with anti-paxillin antibodies. As
shown in Fig 1B, the α4 subunits were all expressed in the
PC12 cells but bound paxillin to differing degrees; while
full-length α4 complexed with high levels of paxillin, α4
with either single mutation bound much lower levels and
α4 with the double mutation showed virtually no bind-
ing. As expected, the α4 subunit lacking the majority of
the cytoplasmic domain did not bind paxillin, illustrating
the specificity of the assay.
To examine the effects of these mutations on α4-mediated
neurite outgrowth, we then grew these PC12 cells on
recombinant Fn fragments containing the V120 region for
24 hrs. The extent of neurite outgrowth correlated with the
degree of paxillin binding to the α4 cytoplasmic domain
(Fig 2A). Either single mutation reduced neurite out-
growth while the double mutation resulted in a complete
loss of α4-mediated neurite outgrowth, with the degree of
outgrowth now being identical to the low level seen with
wild type PC12 cells or with PC12 cells expressing the α4
subunit lacking the majority of the cytoplasmic domain.
To ask whether this effect of perturbing paxillin interac-
tions was specific for α4-mediated neurite outgrowth, we
repeated the experiments with cells expressing wild type
α4 or the double mutation on laminin, collagen or Fn
V120. Laminin and collagen bind to different integrins on
the cell surface (α1β1, α3β1, α6β1 and α7β1 for laminin,
α1β1 and α2β1 for collagen [26]) and promote neurite
outgrowth in PC12 cells [27,28]. Expression of α4, either
wild-type or mutant, had no effect on this neurite out-
growth while, as before, only the cells expressing wild-
type α4 showed enhanced neurite outgrowth on Fn V120BMC Neuroscience 2007, 8:44 http://www.biomedcentral.com/1471-2202/8/44
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(Fig 2B) confirming that the loss of the paxillin associa-
tion with α4 only perturbs α4-mediated neurite out-
growth.
To show directly that paxillin promotes neurite outgrowth
in response to Fn V120 substrates, we over-expressed wild-
type or mutant paxillins in PC12 cells also expressing
wild-type α4. The structure of wild-type paxillin is shown
in Fig 3A, and the two different paxillin mutants used in
the study are shown in Fig. 3B. One lacks the LD4 domain
that promotes neurite outgrowth in PC12 cells grown on
collagen substrates [28]. The other has Tyr to Phe substi-
tutions at Tyr31, Tyr118 and Tyr182. This prevents the phos-
phorylation of Tyr31 and Tyr118 implicated in cell motility
[29] but has no effect on neurite outgrowth on collagen
[28]. Western blot experiments confirmed that tyrosine
phosphorylation was not observed in the triple mutant
paxillin, whilst the wild type and LD4 deletion mutant
forms were recognised by the anti-phosphotyrosine anti-
body (Fig 3C). To determine the relative expression levels
of expressed and endogenous paxillin, we performed
western blots using antibodies against paxillin (that will
recognise both the endogenous and expressed molecules)
and against the FLAG-tag present only in the expressed
form of paxillin. As shown in Fig 3D, there were greater
levels of the expressed paxillins than the endogenous pax-
illin, and the levels of the mutant paxillins were compara-
ble with those seen with the wild-type construct (Fig 3D).
To confirm that the expressed paxillins associated with
α4, we western blotted using anti-paxillin antibodies cell
lysates immunoprecipitated first with anti-α4 and then
with the anti FLAG-tag antibody that detects only the
expressed paxillin. All the expressed paxillins associated
with α4 (Fig 3E). Notably the LD4 deletion mutant asso-
ciated with the integrin, even though the critical residues
for α4 binding have been shown to be present in an Ala176
to Asp275 fragment containing the LD3 and LD4 domains
[30].
Next, we examined neurite outgrowth in PC12 cells co-
expressing wild-type α4 and the different paxillins. In cells
expressing wild-type paxillin, we found enhanced neurite
outgrowth on Fn V120 compared with cells expressing α4
alone (Fig 4). In keeping with the previous studies [28],
no significant difference in the extent of neurite out-
growth on Fn V120 substrates was seen between PC12
cells expressing wild type and the triple tyrosine mutant
paxillin, while the LD4 domain mutant supported neurite
outgrowth to a significantly reduced extent (Fig 4). These
over-expression studies therefore confirm a role for paxil-
Mutations in the paxillin-binding region of the α4 cytoplasmic domain reduce paxillin binding A) The amino acid sequence of  the cytoplasmic domains of the α4 integrins expressed in PC12 cells, starting at the conserved juxtamembrane GFFKR  sequence Figure 1
Mutations in the paxillin-binding region of the α4 cytoplasmic domain reduce paxillin binding A) The amino acid sequence of 
the cytoplasmic domains of the α4 integrins expressed in PC12 cells, starting at the conserved juxtamembrane GFFKR 
sequence. In all cases, the transmembrane and extracellular domains were wild-type human α4 integrin. The different muta-
tions in the paxillin binding domain are underlined, and the cytoplasmic domain deletion (α4del) is also shown. B) The left panel 
shows a streptavidin peroxidase/ECL blot of 1% Triton X-100 lysates of biotin-labelled PC12 cells expressing the different α4 
constructs following immunoprecipitation with anti-human α4 extracellular domain antibodies and SDS-PAGE on 7% gels. 
Note the similar expression of the different mutants. The right panel then shows the same immunoprecipitates western blot-
ted with biotin-labelled anti-paxillin antibodies so as to examine paxillin binding to each integrin cytoplasmic domain in the 
PC12 cells. Note that the single amino acid mutations (α4E983A and α4Y991A) reduce binding, the double mutation (α4EY) 
even more so, and that no binding is seen following deletion of the α4 cytoplasmic domain (α4del).
α4 Chain Mutations:
α4 :             GFFKRQYKSILQEENRRDSWSYINSKSNDD
α4E983A:  GFFKRQYKSILQEANRRDSWSYINSKSNDD
α4Y991A:  GFFKRQYKSILQEENRRDSWSAINSKSNDD
α4EY:         GFFKRQYKSILQEANRRDSWSAINSKSNDD
α4del:         GFFKR
AB
α4E983A
α4 α4Y991A
α4EY
α4del
α4 140
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α4 70
paxillin
ip - α4
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ip - α4
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Mutations in the paxillin-binding region of the α4 cytoplasmic domain inhibit α4-mediated neurite outgrowth Figure 2
Mutations in the paxillin-binding region of the α4 cytoplasmic domain inhibit α4-mediated neurite outgrowth. A) Neurite out-
growth from PC12 cells expressing the different α4 constructs after 24 hrs plated onto recombinant Fn fragments containing 
the V120 sequence (Fn V120, 50 nM) within which the α4-binding LDV motif is present. In each experiments the longest neur-
ites in at least 100 cells were measured and the results normalised to the median values seen in cells expressing wild type α4. 
The data shown are the mean ± SEM of 6 experiments. Note the reduction in the single mutants (* = P < 0.01), and complete 
loss of any α4-mediated outgrowth with the double mutant and cytoplasmic domain deletion (** = P < 0.005), with levels now 
the same as those seen on mock-transfected PC12 cells. B) Neurite outgrowth from mock-transfected PC12 cells and those 
expressing wild-type α4 or the double mutant. Note that, as in A), outgrowth on Fn V120 requires a normal α4 cytoplasmic 
domain while outgrowth on laminin and collagen does not and is similar in all cell lines. C) Representative examples of neurite 
outgrowth in PC12 cells expressing the different α4 constructs.BMC Neuroscience 2007, 8:44 http://www.biomedcentral.com/1471-2202/8/44
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Expression and binding to α4 of paxillin mutant isoforms Figure 3
Expression and binding to α4 of paxillin mutant isoforms. A) Schematic representation of paxillin, showing the position of the 3 
phosphorylated tyrosine residues, the LD domains and the LIM domains. B) The three constructs used to examine paxillin 
function; wild-type paxillin (paxwt), Tyr to Phe mutations of the 3 tyrosines (pax3Y) and an LD4 domain deletion (paxLD4). All 
three contain a FLAG tag. C) Western blotting of lysates from PC12 cells expressing the different paxillin constructs. All three 
are expressed at a similar level, but the pax3Y mutant is not recognised by the anti-phosphotyrosine PY20 antibody. D) West-
ern blots using anti-FLAG tag and anti-paxillin antibodies of lysates from PC12 cells expressing the different paxillin constructs 
with or without co-expression of wild-type α4 integrin, and from mock-transfected PC12 cells. The anti-FLAG (top panel) rec-
ognises only expressed paxillin, while the anti-paxillin antibody (middle panel) recognises both expressed and endogenous pax-
illin. Note that the normal endogenous levels of paxillin (seen in the mock-transfected cells with the anti-paxillin antibody) are 
lower than those seen following expression of the three constructs, with or without α4 (middle panel), and that all cell lines 
contain similar levels of expressed paxillin (top panel). A β-actin loading control is also shown in the lower panel. E) Lysates of 
biotin-labelled PC12 cells expressing either wild-type α4 alone, wild-type paxillin alone or wild-type α4 with the different pax-
illin constructs immunoprecipitated with anti-α4 as in Fig 1 and then re-immunoprecipitated (Re-IP) with anti-FLAG antibodies 
before western blotting with anti-paxillin antibody (top panel) or visualised by streptavidin-peroxidase/ECL (lower panel). All 
four cell lines transfected with α4 constructs express the integrin at similar levels (lower panel), and all expressed (wild-type 
and mutant) paxillins bind to the integrin equally well (upper panel). In the absence of any α4 integrin (wtpax only in upper 
panel), no expressed paxillin is detected, confirming the specificity of the assay. Note that the anti-FLAG antibody used to 
detect paxillin would not be expected to detect the endogenous paxillin associated with α4, and so no band is seen in the α4-
only lane of the upper panel.
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lin in promoting neurite outgrowth on Fn V120 sub-
strates. Taken together with the studies above showing
that association of paxillin with the integrin cytoplasmic
domain is required for outgrowth, they show that the
recruitment of paxillin by α4 integrin represents an
important mechanism for neurite outgrowth on these
embryonic fibronectins.
As outlined in the introduction, the binding of paxillin to
the α4 integrin is inhibited by phosphorylation of Ser988.
The temporal and spatial regulation of paxillin binding
enabled by phosphorylation and dephosphorylation may
have an important physiological role in cell motility, as
both S988A (that inhibits phosphorylation) and S988D
(that mimics phosphorylation) mutations inhibit migra-
tion in cell culture [24]. In the final part of this study,
therefore, we examined the role of phosphorylation of
Ser988 in neurite outgrowth on Fn V120 substrates. We
transfected PC12 cells with either wild type α4 or α4 with
S988A or S988D mutations. As an additional control, we
used a control S990A mutation that does not alter paxillin
binding (Fig 5A). All four α4 constructs were equally
expressed in PC12 cells (Fig 5B). Wild type α4 was not
phosphorylated in PC12 cells as judged by immuno blot-
ting with a phospho-α4 specific antibody whereas it was
heavily phosphorylated in Jurkat cells (a T cell line) (Fig.
5B). In contrast, the α4(S988D) was labelled by this anti-
body in PC12 cells suggesting that this mutation is also
phospho-mimetic with respect to recognition by this anti-
body. We confirmed the effect of these mutations on the
binding of paxillin to the α4 cytoplasmic domain by
immunoprecipitating α4 from lysates of cells expressing
each of the four different α4 subunits and detecting paxil-
lin by immunoblotting. As expected, no associated paxil-
lin was seen with the phospho-mimicking S988D
mutation, whilst all others bound paxillin as expected (Fig
6A). Lastly, we examined neurite outgrowth in PC12 cells
expressing each of the four α4 subunits on Fn V120. As
before, wild-type α4 promoted neurite outgrowth and this
was not affected by the S988A or S990A mutations. In
contrast, however, the S988D mutation that blocked pax-
illin binding showed no α4-mediated neurite outgrowth,
as the levels of outgrowth were identical to those of PC12
cells not expressing α4 integrin (Fig 6B). We conclude that
mutations that mimic phosphorylation of Ser988 will pre-
vent paxillin binding in PC12 cells, and therefore inhibit
the neurite outgrowth promoted by α4 integrin on Fn
V120 substrates. However, the lack of detectable phos-
phorylation of wild-type α4 in the PC12 cells and the effi-
cacy of α4(S988A) in promoting neurite outgrowth
suggests that the reversibility of paxillin binding enabled
by phosphorylation of Ser988 is not necessary for neurite
outgrowth.
Discussion
We have shown that the association of the adaptor pro-
tein, paxillin, with the α4 integrin cytoplasmic domain is
required for α4-mediated neurite outgrowth in PC12 cells
on embryonic Fns that are expressed during nerve regen-
eration. In the absence of this association, the enhanced
neurite outgrowth on Fn V120 is lost. Conversely, overex-
pression of paxillin enhances α4-dependent neurite out-
growth on this substrate. As alternative splicing of the Fn
primary gene transcript following PNS injury increases the
number of Fns containing V120 in the regenerating nerve,
and α4 is expressed on regenerating growth cones in vivo
[16,17], we suggest that the α4-paxillin interaction may
play a key role in PNS regeneration. The upregulation of
different ECM molecules during PNS regeneration sug-
gests that other integrins will also contribute to regenera-
tion. Two candidates are α5β1, that is also expressed on
regenerating growth cones in vivo [2], and α7β1, a lam-
inin receptor expressed on a subset of DRG neurons and
also shown to be required for normal regeneration of
motor neurones in the facial nerve [31,32]. However, as
α4 and the closely related α9 are the only integrin α sub-
units reported to bind paxillin directly [20,33], it is likely
that these integrins will activate different and parallel
downstream pathways so providing an enhanced regener-
ative response triggered by the change in Fn splicing.
The demonstration of a functional requirement for paxil-
lin binding to a specific integrin to promote neurite out-
growth extends previous work on signalling within
growth cones. Paxillin is localised within neuronal growth
cones within dynamic focal adhesions that assemble at
the leading edge, enlarge and finally disassemble while
remaining in place as the growth cone advances [34]. It
becomes tyrosine phosphorylated on neurite outgrowth
[35,36]. Tyrosine phosphorylation of paxillin at Tyr31 and
Tyr118 provide a binding site for the adaptor protein Crk
[37,38]. Overexpression of Crk promotes neurite out-
growth in PC12 cells [39], and also promotes cell motility
in a bladder cancer cell line [29]. Surprisingly, therefore,
but in agreement with others [28], we find no evidence
that inhibiting tyrosine phosphorylation by expression of
a paxillin with Tyr to Phe mutations in these residues
inhibits the ability of over-expressed paxillin to enhance
neurite outgrowth. Two other regions of paxillin have
been implicated in neurite outgrowth signalling. First, Ser
85 (Ser 83 in the rat) that is phosphorylated by p38 MAPK.
This phosphorylation promotes outgrowth that can be
inhibited by a Ser to Ala mutation in this position [40].
Second, the LD4 domain within the leucine-rich domains,
that provides a binding site for a number of other signal-
ling proteins [41,42] and deletion of which inhibits neur-
ite outgrowth in PC12 cells growing on collagen
substrates [28]. Our results show markedly less neurite
outgrowth following expression of the LD4 deletionBMC Neuroscience 2007, 8:44 http://www.biomedcentral.com/1471-2202/8/44
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mutant than full-length paxillin, suggesting an important
role of the LD4 domain in α4 integrin-mediated neurite
formation.
At least three possible mechanisms by which the LD4
domain might promote neurite outgrowth have been
described. First, by the recruitment of the focal adhesion
kinases FAK and Pyk2, both of which interact directly with
the LD4 domain [41], are co-immunoprecipitated with
paxillin in PC12 cells [43] and are activated by interaction
with the α4 cytoplasmic domain in T cells [44]. Activation
of these kinases occurs during growth factor-induced neu-
rite outgrowth in PC12 cells, and inhibition of their activ-
ity by expression of a C-terminal construct (PRNK and
FRNK, which act as dominant negative isoforms) blocks
this outgrowth [28]. Second, by recruitment of the Arf-
GAP PKL. This in turn recruits the p21-associated kinase
(PAK1) via a linking interaction with PIX [45], and PAK1
localisation to the membrane in PC12 cells has been
shown to promote neurite outgrowth [46], potentially via
the activation of cdc42 [42]. Third, by the regulation of
the Rho GTPase Rac, as demonstrated by the prolonged
levels of Rac activation, loss of directional migration and
randomly-orientated lamellopodia formation in CHO
cells expressing an LD4 deletion mutant of paxillin [47].
As expression of a constitutively active form of Rac in
PC12 cells promotes cell spreading but not neurite out-
growth, whilst dominant negative Rac inhibits neurite
outgrowth [46], precise regulation of Rac activity is clearly
essential for neurite formation by PC12 cells.
The LD4 domain of paxillin contributes to α4-mediated neu- rite outgrowth Figure 4
The LD4 domain of paxillin contributes to α4-mediated neu-
rite outgrowth. Neurite outgrowth of PC12 cells expressing 
α4 and the different paxillin constructs, measured as in Fig. 1. 
The data shown are the mean ± SEM of 3 experiments. Note 
that paxillin over-expression enhances neurite outgrowth, 
but the paxillin lacking the LD4 domain (LD4pax) does so 
less effectively than wild-type paxillin (wtpax) or paxillin with 
Tyr to Phe mutations of the 3 tyrosines (3Ypax) (** = P < 
0.05 as compared to the level of outgrowth in cells express-
ing α4 and wtpax).
*
Mutations of Ser988 in the α4 cytoplasmic domain mimic phosphorylation Figure 5
Mutations of Ser988 in the α4 cytoplasmic domain mimic phosphorylation. A) The amino acid sequence of the cytoplasmic 
domains of the α4 integrins expressed in PC12 cells, starting at the conserved juxtamembrane GFFKR sequence. As in Fig 1, 
the transmembrane and extracellular domains were wild-type human α4 integrin. The different mutations are underlined. B) 
The left panel shows an anti-phospho Ser988 α4 integrin blot of 1% Triton X-100 lysates of biotin-labelled PC12 cells express-
ing the different α4 constructs following immunoprecipitation with anti-human α4 extracellular domain antibodies and SDS-
PAGE on 7% gels. Note that α4 integrins with the phospho-mimicking mutation S988D are labelled, while those with the 
S988A and control S990A mutations are not. Jurkat T cells are shown as a positive control. The right hand panel then shows 
the same blot stripped and reprobed with streptavidin peroxidase/ECL to confirm the similar expression of the different α4 
constructs.
A
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α4 70
       β1
α4 140
PC12 + α4S988A
PC12 + α4
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α4S990A:  GFFKRQYKSILQEENRRDSWAYINSKSNDDBMC Neuroscience 2007, 8:44 http://www.biomedcentral.com/1471-2202/8/44
Page 8 of 11
(page number not for citation purposes)
Directional cell migration is associated with high levels of
Rac activity at the leading edge of the cell [48]. A key ques-
tion for future studies will therefore be the role of paxillin
and α4 integrin in the spatial control of Rac activity within
the growth cone. The phosphorylated α4 integrins found
in T cell lines will not bind paxillin [22], and are localised
to the leading edge of migrating CHO cells, while non-
phosphorylated integrins are found in the lateral edges
[23]. As the α4-paxillin interaction inhibits Rac activity
and lamellopodia formation, the extension of cellular
protrusions driven by Rac and required for movement are
therefore restricted to the leading edge of the cell and
directionality of migration is achieved [23,49]. A mecha-
nism by which the paxillin-integrin interaction reduces
Rac activity is provided by recent work showing that
recruitment of the Arf-GAP GIT1 inactivates Arf activity,
which in turn results in decreased Rac activation [49].
Integrin phosphorylation therefore plays a key role in
directional migration in some non-neural cells by provid-
ing a mechanism for the spatial regulation of paxillin dis-
sociation from the α4 cytoplasmic domain.
Conclusion
Peripheral nerve repair is associated with a re-expression
of embryonic isoforms of fibronectin that contain a bind-
ing site for the α4β1 integrin. This integrin is expressed on
regenerating growth cones and promotes neurite out-
growth on embryonic fibronectins in cell culture. Using
PC12 neuronal cells as a model system, we have shown
here that the interaction of the adaptor protein paxillin
with the integrin cytoplasmic domain is required for this
outgrowth. We have also found that, in contrast to studies
using T cells, there is no biochemical evidence for phos-
phorylation of α4 integrins in PC12 cells, suggesting that
the dissociation of paxillin from the integrin mediated by
this phosphorylation is either not required for growth
cone motility or is achieved through different means. This
points to potentially interesting differences between the
mechanisms of two distinct forms of cell movement;
directional migration in isolated cells and growth cone
motility at the end of a cell process or axon.
Methods
Reagents
The following antibodies were used: mouse anti-human
α4, clone HP2/1 (Chemicon); hamster anti-rat β1, clone
HA2/5 (Pharmingen), mouse anti-paxillin, clone 349
(Transduction Laboratories), mouse anti-FLAG M2
(Sigma), anti-phosphotyrosine antibody PY20 (Transduc-
tion Laboratories). The rabbit phospho-specific anti-α1
Mutations of Ser988 in the α4 cytoplasmic domain that mimic phosphorylation reduce paxillin binding and inhibit α4-mediated  neurite outgrowth Figure 6
Mutations of Ser988 in the α4 cytoplasmic domain that mimic phosphorylation reduce paxillin binding and inhibit α4-mediated 
neurite outgrowth. A) Lysates of biotin-labelled PC12 cells expressing the different α4 constructs immunoprecipitated with 
anti-α4 antibody as in Fig 1 and visualised by streptavidin peroxidase/ECL (upper panel) or by western blotting with anti-paxillin 
antibody (lower panel). Note that the phospho-mimicking S988D mutation prevents paxillin binding and co-immunoprecipita-
tion. B) Neurite outgrowth of PC12 cells expressing the different α4 constructs and mock-transfected PC12 cells measured as 
in Fig. 1. The data shown are the mean ± SEM of 3 experiments. Note that the S988D mutation also inhibits α4-mediated neu-
rite outgrowth (* = P < 0.01).
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antibody was generated against a synthetic peptide con-
taining phospho serine at Ser988 as previously described
[22]. Recombinant Fn fragments encompassing repeats
III-8-15 and containing all three possible combinations of
the V region (and therefore the α4β1 integrin binding
site) were prepared as described previously [17].
Integrin constructs
Construction of pLXIN (Clontech) retroviral vectors
encoding α4 integrin chimeras was previously described
[17]. α4 cytoplasmic domain mutations were introduced
in the full length α4 chain by site-directed mutagenesis
using the QuickChange kit (Stratagene). Alanine substitu-
tions were introduced at Y991 and E983 using the follow-
ing primers: 5'-C AGA AGA GAC AGT TGG AGT GCT ATC
AAC AGT AAA AGC AAT G-3' (sense) and the correspond-
ing antisense primer for substitution of Y991 (Y991A),
and 5'-C AAA TCT ATC CTA CAA GAA GCA AAC AGA
AGA GAC AGT TGG-3' (sense) with the matching anti-
sense for substitution of E983 (E983A). Double mutants
were generated by successive rounds of mutagenesis, first
E983, followed by Y991 substitution. Alanine and aspartic
acid substitutions were introduced at S988 and S990
using the following sense primers: S988A, 5'-C CTA CAA
GAA GAA AAC AGA AGA GAC GCT TGG AGT TAT ATC
AAC AG-3'; S988D, 5'-C CTA CAA GAA GAA AAC AGA
AGA GAC GAT TGG AGT TAT ATC AAC AG-3'; S990A, 5'-
GAA AAC AGA GAC AGT TGG GCT TAT ATC AAC AGT
AAA AGC-3'. Base substitution at the sites of mutation was
confirmed by DNA sequencing. The nomenclature used
for the different constructs is as follows: α4Y991A,
α4E983A, α4EY, α4S988A, α4S988D, α4S990A.
Paxillin constructs
The cDNA sequence encoding wild-type chicken paxillin,
and paxillin with three Y to F substitutions at Y31, Y118
and Y 182, were a gift from I Dikic (Uppsala, Sweden).
PCR was used to generate a Xba I site replacing the ATG of
paxillin at the 5' end, and a Xho I site at the 3'end. A Not I-
Xba I linker fragment including a Xho I site and a FLAG tag,
DYKDDDDK, was ligated at the 5' end of the paxillin
sequence. The sequence encoding the FLAG tag in frame
with paxillin was excised using Xho I and cloned into the
pMSCVpuro retroviral vector (Clontech). Paxillin lacking
the LD4 domain was generated by two sequential rounds
of site-directed mutagenesis, using the following deletion
primers: 5'-GCT TCT TCA GCT ACA CGA GAA GAG CTG
ATG GCG TCC CTC-3' and 5'-GAG GGA CGC CAT CTC
TTC TCG TGT AGC TGA AGA AGC-3'. All cDNAs were
sequenced.
Cell culture
COS7, NIH 3T3 and GP+86 cells were grown in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal calf serum (FCS), penicillin/streptomycin,
and 2 mM glutamine (Sigma). Rat pheochromocytoma
(PC12) cells were grown on Poly-D-Lysine-coated tissue
culture flasks in DMEM supplemented with 10% horse
serum (HS), 5% FCS, penicillin/streptomycin, and 2 mM
glutamine. For priming with NGF, PC12 cells were pas-
saged onto collagen-coated (calf-skin type I collagen;
Sigma) dishes at a density of 104 cells/cm2 and cultured
for 4–5 days in DMEM complemented with 1% ITS+™
premix (BD Biosciences) and 50 ng/ml 2.5S NGF (Sero-
tec). For neurite outgrowth assays, NGF-primed cells were
passaged by gentle trituration and cultured on the desired
substrate in the same defined medium.
Transfection and selection of stable clones
The constructs were transfected into the GP+86 packaging
cell line, using FuGENE 6 as transfection reagent (Roche).
Cells were maintained in DMEM supplemented with 10%
FCS, penicillin/streptomycin, 2 mM glutamine and 1 mg/
ml G418 (Life Technologies) for pLXIN construct or 2 μg/
ml puromycin for pMSCV constructs until clones
appeared. The GP+86 cells were then replated and when
at 60–70% confluence, were washed and medium with-
out G418 or puromycin added. The conditioned medium
was collected after 24 h, filtered (0.45 μm pore size), and
either used immediately or aliquoted, frozen and kept at -
70°C. Virus titer was determined using NIH 3T3 cells and
equalized. PC12 cells were transfected using polybrene,
and selected and maintained with 1 mg/ml G418 or 2 μg/
ml puromycin.
Neurite outgrowth assay
All neurite outgrowth assays were performed in 4-well tis-
sue culture plates. For preparation of the substrates, lig-
ands (recombinant Fn fragments, type-1 collagen (Sigma)
or laminin-1 (Sigma)) were diluted into PBS, and depos-
ited as 30 μl drops in the centre of the wells. Where recom-
binant Fn fragments were used, the dishes were first
coated with 10 μg/ml anti-IgG1 Fc for 3 h at RT, washed 2
× with PBS and then post-adsorbed with the various frag-
ments overnight at 4°C. The wells were washed 3 × with
PBS, and PC12 cells were deposited in 30 μl drops on the
substrates at a density of 5 × 102/cm2. After 1 h, when the
cells were attached, the medium was added, to a final vol-
ume of 200 μl. Measures were taken after 12 h, and 24 h
(separate sets of dishes). Dishes were viewed under a Zeiss
phase microscope and random fields were recorded using
a digital camera and analyzed using the Openlab software
(Improvision). The length of neurites was determined
using the Openlab software. Determinations were made
on at least 5 separate experiments, and the longest neurite
of at least 100 PC12 cells/well was measured. Untrans-
fected and mock-transfected cells were used as negative
controls. Assays were conducted on both experimental
and control cell lines in parallel, and the results normal-
ized to the control values. Each assay was repeated 5 timesBMC Neuroscience 2007, 8:44 http://www.biomedcentral.com/1471-2202/8/44
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with three independently generated cell lines, and the
mean determined. Statistical analysis was performed
using Students t test.
Immunoprecipitations and Western blotting
Cell surface molecules were labelled with 0.1 mg/ml
NHS-LC-Biotin (Pierce) in PBS at 37°C for 30 min. Cells
were washed three times with cell wash buffer (50 mM
Tris-HCl pH 7.5, 0.15 M NaCl, 1 mM CaCl2, 1 mM
MgCl2), scraped, and lysed on ice for 30 min in extraction
buffer: cell wash buffer plus 1% Triton X-100, 0.05%
Tween 20, 2 mM PMSF, 1 μg/ml pepstatin A, 2 μg/ml
aprotinin, 5 μg/ml leupeptin, 2 mM sodium vanadate, 4
mM sodium pyrophospate, and 2 mM sodium fluoride.
After clarification by centrifuging at 14000 rpm for 20 min
at 4°C, the cell lysates were incubated with 30 μl protein
A-sepharose (Pharmacia). The lysates were pre-cleared by
two sequential 2 h incubations (to remove proteins show-
ing non-specific interactions with protein-A) and immu-
noprecipitations were then carried out overnight at 4°C.
Where hamster or mouse monoclonal antibodies were
used, rabbit anti-hamster or rabbit anti-mouse antisera
(Nordic Immunological Laboratories) were also added to
the tubes (1 in 250). All antibodies were used at a dilution
of 1:250. The beads were washed 5 × with immunoprecip-
itation buffer (identical to cell wash buffer except for 0.5
M NaCl and 1% NP40) and the precipitated polypeptides
were extracted with SDS sample buffer. Precipitated cell
surface biotin-labelled molecules were separated by SDS-
PAGE under non-reducing conditions and detected with
streptavidin-peroxidase followed by ECL (Amersham).
Co-precipitated paxillin was detected by immuno-blot-
ting of reduced immunoprecipitates with anti-paxillin
antibody, followed by anti-mouse-peroxidase conjugated
antibody and ECL.
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